Related Experiment Videos
Monoclonal antibodies in immunosuppression
1Department of Surgery, Addenbrooke's Hospital, Cambridge, United Kingdom.
Annals of the Academy of Medicine, Singapore
|July 1, 1991
Summary
Monoclonal antibodies targeting CDW52 show potent immunosuppression for organ transplantation. While IL-2 receptor antibodies were effective in primates, clinical benefits in preventing rejection are not yet proven.
Area of Science:
- Immunology
- Transplantation Medicine
- Biotechnology
Background:
- Monoclonal antibodies (mAbs) are investigated for immunosuppression in organ transplantation.
- Primate models are used for preliminary studies before human clinical trials.
Purpose of the Study:
- To evaluate the efficacy of different monoclonal antibodies in preventing organ transplant rejection.
- To identify optimal targets and strategies for antilymphocyte therapy.
Main Methods:
- Studies utilized a primate renal allograft model and clinical pilot studies.
- Monoclonal antibodies targeting CDW52 (Campath-1) and the IL-2 receptor were assessed.
- Monitoring included target antigen expression, free antibody levels, and antiglobulin response.
Main Results:
- CDW52-targeting antibodies (IgM and IgG2b) demonstrated powerful immunosuppressive effects.
- An IL-2 receptor IgG2b antibody showed immunosuppression in primates but not significant clinical benefit in preventing rejection.
- Patient monitoring for antigen expression, free antibody, and antiglobulin response is necessary.
Conclusions:
- CDW52 is a promising target for antilymphocyte therapy in transplantation.
- Further research is needed to optimize antibody selection, understand effector mechanisms, and manage antiglobulin responses for effective immunosuppression.